Page 72 - Looking Statement News Today

Financing composed of a €3.0 million R&D innovation loan and a 1.3 million reimbursable advance Cash position strengthened and runway extended Regulatory News: Lysogene (FR0013233475 LYS)

Press release content from Business Wire. The AP news staff was not involved in its creation.

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Trutankless, Inc. (OTCQB: TKLS) today announced that December 10th, 2021 has been set as the record date for the dividend of shares of common...

/PRNewswire/ -- Trutankless, Inc. (OTCQB: TKLS) today announced that December 10th, 2021 has been set as the record date for the dividend of shares of common...

Merck known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. . “This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy,” said Rob Davis, ...

20.11.2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron ...

Merck known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron Pharma Inc. at a purchase price of $180 per share in cash, without interest and less applicable tax withholding. As of the tender offer expiration at 5:00 p.m., Eastern Time, on Nov. ...

/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today...

/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today...